Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Wallach

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Journal of Psychoactive Drugs|July 26, 2022
The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and MetabolitesPhilip Wolfson, Rob Cole, Kara Lynch, et al.
Drug Design, Development and Therapy|May 13, 2017
Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogsYuren Wang, Jason Wallach, Stephanie Duane, et al.
Metabolites|May 24, 2024
In Vivo and In Vitro Metabolic Fate and Urinary Detectability of Five Deschloroketamine Derivatives Studied by Means of Hyphenated Mass SpectrometryFabian Frankenfeld, Lea Wagmann, Anush Abelian, et al.
Toxicology and Applied Pharmacology|June 16, 2026
In-depth in vivo and in vitro investigation of metabolism and detectability of three novel methylprolintane psychostimulants by hyphenated mass spectrometryLea Wagmann, Anica Herter, Michael B Dybek, et al.
Archives of Toxicology|May 25, 2026
Metabolic fate and detectability of three novel fluoroprolintane psychostimulants: in vitro and in vivo characterization by hyphenated mass spectrometryLea Wagmann, Anica Herter, Michael B Dybek, et al.
Current Neuropharmacology|October 21, 2016
New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, "LC-(High Resolution)-MSn" and "LC-(High Resolution)-MS/MS"Julian A A Michely, Sascha K Manier, Achim T Caspar, et al.
Neuropharmacology|August 14, 2016
Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist propertiesHeather Kang, Pojeong Park, Zuner A Bortolotto, et al.
Drug Testing and Analysis|September 12, 2015
Syntheses and analytical characterizations of N-alkyl-arylcyclohexylaminesJason Wallach, Tristan Colestock, Brian Cicali, et al.
Drug Testing and Analysis|October 13, 2015
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|May 18, 2017
Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analoguesTristan Colestock, Jason Wallach, Matt Mansi, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Psychoactive Drugs|July 26, 2022
The Pharmacokinetics of Ketamine in the Breast Milk of Lactating Women: Quantification of Ketamine and MetabolitesPhilip Wolfson, Rob Cole, Kara Lynch, et al.
Drug Design, Development and Therapy|May 13, 2017
Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogsYuren Wang, Jason Wallach, Stephanie Duane, et al.
Metabolites|May 24, 2024
In Vivo and In Vitro Metabolic Fate and Urinary Detectability of Five Deschloroketamine Derivatives Studied by Means of Hyphenated Mass SpectrometryFabian Frankenfeld, Lea Wagmann, Anush Abelian, et al.
Toxicology and Applied Pharmacology|June 16, 2026
In-depth in vivo and in vitro investigation of metabolism and detectability of three novel methylprolintane psychostimulants by hyphenated mass spectrometryLea Wagmann, Anica Herter, Michael B Dybek, et al.
Archives of Toxicology|May 25, 2026
Metabolic fate and detectability of three novel fluoroprolintane psychostimulants: in vitro and in vivo characterization by hyphenated mass spectrometryLea Wagmann, Anica Herter, Michael B Dybek, et al.
Current Neuropharmacology|October 21, 2016
New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, "LC-(High Resolution)-MSn" and "LC-(High Resolution)-MS/MS"Julian A A Michely, Sascha K Manier, Achim T Caspar, et al.
Neuropharmacology|August 14, 2016
Ephenidine: A new psychoactive agent with ketamine-like NMDA receptor antagonist propertiesHeather Kang, Pojeong Park, Zuner A Bortolotto, et al.
Drug Testing and Analysis|September 12, 2015
Syntheses and analytical characterizations of N-alkyl-arylcyclohexylaminesJason Wallach, Tristan Colestock, Brian Cicali, et al.
Drug Testing and Analysis|October 13, 2015
Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Simon D Brandt, Pierce V Kavanagh, Folker Westphal, et al.
Drug Testing and Analysis|May 18, 2017
Syntheses, analytical and pharmacological characterizations of the 'legal high' 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo) and analoguesTristan Colestock, Jason Wallach, Matt Mansi, et al.
Pageof 4